Safety and efficacy of once-weekly carfilzomib (K) dosing in frail patients (pts): a subgroup analysis from the phase 3 ARROW study

被引：0
|
作者：
Mateos, Maria-Victoria [1 ]
Ludwig, Heinz [2 ]
Kumar, Shaji [3 ]
Rosenbaum, Cara [4 ]
Huang, Mei [5 ]
Goldrick, Amanda [5 ]
Blaedel, Julie [5 ]
Dimopoulos, Meletios A. [6 ]
机构：
[1] Univ Hosp Salamanca IBSAL, Salamanca, Spain
[2] Wilhelminenspital Stadt Wien, Wilhelminen Canc Res Inst, Vienna, Austria
[3] Mayo Clin, Rochester, MN USA
[4] Weill Cornell Med, New York, NY USA
[5] Amgen Inc, Thousand Oaks, CA 91320 USA
[6] Univ Athens, Sch Med, Athens, Greece
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期
关键词：
carfilzomib; frailty; Relapsed Refractory MM;
D O I：
10.1016/j.clml.2019.09.047
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OAB-046
引用
收藏
页码：E31 / E32
页数：2
相关论文
共 13 条
  • [1] Safety and Efficacy of Once-Weekly Carfilzomib (K) Dosing in Frail Patients (pts): A Subgroup Analysis from the Phase 3 ARROW Study
    Mateos, Maria-Victoria
    Ludwig, Heinz
    Kumar, Shaji
    Rosenbaum, Cara
    Huang, Mei
    Goldrick, Amanda
    Blaedel, Julie
    Dimopoulos, Meletios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S320 - S321
  • [2] Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (ARROW) and comparison with ENDEAVOR
    Takezako, Naoki
    Shibayama, Hirohiko
    Handa, Hiroshi
    Hagiwara, Shotaro
    Ozaki, Shuji
    Suzuki, Kenshi
    Kosugi, Hiroshi
    Ri, Masaki
    Sugiura, Isamu
    Choi, Ilseung
    Miyamoto, Toshihiro
    Iida, Shinsuke
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2021, 113 (02) : 219 - 230
  • [3] Patient-Reported Outcomes (PROs) From the Phase 3 ARROW Study Comparing Once-Weekly versus Twice-Weekly Carfilzomib Dosing in Relapsed and Refractory Multiple Myeloma (RRMM)
    Moreau, Philippe
    Kumar, Shaji
    Boccia, Ralph
    Iida, Shinsuke
    Goldschmidt, Hartmut
    Cocks, Kim
    Zahlten-Kumeli, Anita
    Yucel, Emre
    Panjabi, Sumeet
    Dimopoulos, Meletios
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S240 - S240
  • [4] Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR
    Naoki Takezako
    Hirohiko Shibayama
    Hiroshi Handa
    Shotaro Hagiwara
    Shuji Ozaki
    Kenshi Suzuki
    Hiroshi Kosugi
    Masaki Ri
    Isamu Sugiura
    Ilseung Choi
    Toshihiro Miyamoto
    Shinsuke Iida
    International Journal of Hematology, 2021, 113 : 219 - 230
  • [5] Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and ARROW Trials
    Dimopoulos, Meletios A.
    Moreau, Philippe
    Iida, Shinsuke
    Huang, Shang-Yi
    Takezako, Naoki
    Chng, Wee Joo
    Zahlten-Kumeli, Anita
    Sersch, Martina A.
    Li, Julia
    Huang, Mei
    Lee, Jae Hoon
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2019, 110 (04) : 466 - 473
  • [6] A phase 1b study of once-weekly carfilzomib combined with lenalido-mide and dexamethasone (wKRd) in patients (pts) with newly diagnosed multiple myeloma (NDMM)
    Alsina, Melissa
    Landgren, C. Ola
    Raje, Noopur
    Niesvizky, Ruben
    Bensinger, William I.
    Berdeja, Jesus
    Kovacsovics, Tibor
    Vesole, David
    Fang, Belle
    Kimball, Amy
    Siegel, David S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10) : E52 - E52
  • [7] Carfilzomib (K) in relapsed and refractory multiple myeloma (RRMM): frailty subgroup analysis from phase 3 ASPIRE and ENDEAVOR
    Facon, Thierry
    Niesvizky, Ruben
    Weisel, Katja
    Bringhen, Sara
    Ho, P. Joy
    Obreja, Mihaela
    Yang, Zhao
    Klippel, Zandra
    Blaedel, Julie
    Mezzi, Khalid
    Siegel, David S.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10) : E266 - E266
  • [8] Once-weekly (70 mg/m2) vs twice-weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, ARROW, and CHAMPION-1 trials
    Moreau, Philippe
    Stewart, Keith A.
    Dimopoulos, Meletios
    Siegel, David
    Facon, Thierry
    Berenson, James
    Raje, Noopur
    Berdeja, Jesus G.
    Orlowski, Robert Z.
    Yang, Hui
    Ma, Haijun
    Klippel, Zandra
    Zahlten-Kumeli, Anita
    Mezzi, Khalid
    Iskander, Karim
    Mateos, Maria-Victoria
    CANCER MEDICINE, 2020, 9 (09): : 2989 - 2996
  • [9] Carfilzomib (K) in Relapsed and Refractory Multiple Myeloma (RRMM): Frailty Subgroup Analysis from Phase 3 ASPIRE and ENDEAVOR
    Facon, Thierry
    Niesvizky, Ruben
    Weisel, Katja
    Bringhen, Sara
    Ho, P. Joy
    Obreja, Mihaela
    Yang, Zhao
    Klippel, Zandra
    Blaedel, Julie
    Mezzi, Khalid
    Siegel, David
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S320 - S320
  • [10] Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials
    Meletios A. Dimopoulos
    Philippe Moreau
    Shinsuke Iida
    Shang-Yi Huang
    Naoki Takezako
    Wee Joo Chng
    Anita Zahlten-Kumeli
    Martina A. Sersch
    Julia Li
    Mei Huang
    Jae Hoon Lee
    International Journal of Hematology, 2019, 110 : 466 - 473
12